Staidson Beijing Biopharma (300204) — Long-term Investment Intensity
Staidson Beijing Biopharma (300204) has a Long-term Investment Intensity of 20.4% as of December 2019. Long-term investments of CN¥380.77 Million represent 20.4% of total assets of CN¥1.86 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Staidson Beijing Biopharma asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Staidson Beijing Biopharma Long-term Investment Intensity (2015–2019)
This chart shows how Staidson Beijing Biopharma's Long-term Investment Intensity has evolved across 5 annual periods from 2015 to 2019. As of December 2019, the intensity stands at 20.4%, reflecting long-term investments of CN¥380.77 Million against total assets of CN¥1.86 Billion CNY. For the complete balance sheet picture, see Staidson Beijing Biopharma asset portfolio.
Annual Long-term Investment Intensity for Staidson Beijing Biopharma (2015–2019)
The table below presents the year-by-year Long-term Investment Intensity for Staidson Beijing Biopharma from 2015 to 2019, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read total liabilities of Staidson Beijing Biopharma for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (CNY) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 20.4% | CN¥380.77 Million | CN¥1.86 Billion | ▼ -8.1 pp |
| 2018 | 28.6% | CN¥792.60 Million | CN¥2.77 Billion | ▲ +12.0 pp |
| 2017 | 16.6% | CN¥435.88 Million | CN¥2.63 Billion | ▲ +10.1 pp |
| 2016 | 6.5% | CN¥152.98 Million | CN¥2.35 Billion | ▲ +6.1 pp |
| 2015 | 0.4% | CN¥8.19 Million | CN¥2.07 Billion | — |